At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 86 enrolled
Drug / intervention
SAR442970 +1 moredrug
Likely dose
SAR442970 1 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study Assessing the Efficacy and Safety of an Anti-TNF-OX40L NANOBODY® Molecule, SAR442970, in Participants With Moderate to Severe Hidradenitis Suppurativa
In Brief
A Phase 2 clinical trial evaluating SAR442970 and Placebo for Hidradenitis Suppurativa. Completed, enrolled 86 participants across 45 sites in 15 countries.
Detailed Summary
This was a Phase 2 study in adult participants with moderate to severe hidradenitis suppurativa (HS). The purpose of the study was to evaluate the efficacy and safety of SAR442970 compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa
CountriesAustralia, Belgium, Canada, Chile, Czechia, Denmark, France, Germany, Greece, Italy, Netherlands, Poland, Spain, Sweden, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
First PostedMay 2023
Enrollment StartJun 2023
Primary CompletionAug 2024
Study CompletionJan 2025
TodayJul 2026
First PostedMay 9, 2023
Enrollment StartJun 6, 2023
Primary CompletionAug 22, 2024
Study CompletionJan 9, 2025
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 3.1 years ago
Interventions
SAR442970drug
1 mL extractable volume of 150 mg/mL SAR442970 filled in 2 mL glass vial
Placebodrug
1 mL extractable volume of placebo filled in 2 mL glass vial